Advances in Traditional Chinese Medicine for Managing Diminished Ovarian Reserve: Mechanisms and Clinical Insights.

IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL
Drug Design, Development and Therapy Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S505689
Yonghui Liu, Mingchan Wei, Yasheng Deng, Yanping Fan, Yiqing Zheng, Zhaobing Ni, Jiang Lin
{"title":"Advances in Traditional Chinese Medicine for Managing Diminished Ovarian Reserve: Mechanisms and Clinical Insights.","authors":"Yonghui Liu, Mingchan Wei, Yasheng Deng, Yanping Fan, Yiqing Zheng, Zhaobing Ni, Jiang Lin","doi":"10.2147/DDDT.S505689","DOIUrl":null,"url":null,"abstract":"<p><p>Diminished Ovarian Reserve (DOR) is characterised by a decrease in the number and quality of oocytes, accompanied by biological markers such as a decrease in anti-Müllerian hormone (AMH), a decrease in the sinus follicle count (AFC), and an increase in follicle stimulating hormone (FSH). In response to the limitations of modern medical treatments, traditional Chinese medicine (TCM) has demonstrated unique advantages in the treatment of DOR. In this paper, we systematically reviewed the literature in the past decade to analyse the scientific content of TCM intervention in DOR from the dimensions of molecular mechanism and clinical application. It was found that single components (paeoniflorin, <i>Epimedium</i> glycosides, etc.), TCM pairs (<i>Cuscuta chinensis-Sambucus nigra and Semencuspidatae</i>-<i>Epimedium</i>), TCM combinations (Liuweidihuangwan, Haifuyuyuyuitang, <i>Angelica sinensis-Paeonia lactiflora</i>, etc.), and a variety of acupuncture therapies can improve the ovarian function through a multi-targeted modulation mechanism: ① regulating the signalling pathways, such as PI3K/AKT, to promote the development of the follicle; ②regulating the hypothalamic-pituitary-ovarian axis balance hormone levels; ③enhance anti-oxidative stress through Nrf2/HO-1/NLRP3 signalling; ④inhibit the expression of granulosa cell apoptosis-related factors (Bax/Caspase-3). Clinical data showed that TCM interventions significantly increased AMH levels, increased AFC and decreased FSH levels in patients. The study confirms that TCM exerts therapeutic advantages through multi-component synergistic effects, from improving the ovarian microenvironment, regulating reproductive endocrinology, delaying follicular atresia, etc. which provides a theoretical basis and practical reference for the integrated treatment of DOR. It is suggested that standardised clinical studies should be carried out to establish an evaluation system for the efficacy of TCM and to promote the development of precise treatment options.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5597-5614"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228491/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S505689","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Diminished Ovarian Reserve (DOR) is characterised by a decrease in the number and quality of oocytes, accompanied by biological markers such as a decrease in anti-Müllerian hormone (AMH), a decrease in the sinus follicle count (AFC), and an increase in follicle stimulating hormone (FSH). In response to the limitations of modern medical treatments, traditional Chinese medicine (TCM) has demonstrated unique advantages in the treatment of DOR. In this paper, we systematically reviewed the literature in the past decade to analyse the scientific content of TCM intervention in DOR from the dimensions of molecular mechanism and clinical application. It was found that single components (paeoniflorin, Epimedium glycosides, etc.), TCM pairs (Cuscuta chinensis-Sambucus nigra and Semencuspidatae-Epimedium), TCM combinations (Liuweidihuangwan, Haifuyuyuyuitang, Angelica sinensis-Paeonia lactiflora, etc.), and a variety of acupuncture therapies can improve the ovarian function through a multi-targeted modulation mechanism: ① regulating the signalling pathways, such as PI3K/AKT, to promote the development of the follicle; ②regulating the hypothalamic-pituitary-ovarian axis balance hormone levels; ③enhance anti-oxidative stress through Nrf2/HO-1/NLRP3 signalling; ④inhibit the expression of granulosa cell apoptosis-related factors (Bax/Caspase-3). Clinical data showed that TCM interventions significantly increased AMH levels, increased AFC and decreased FSH levels in patients. The study confirms that TCM exerts therapeutic advantages through multi-component synergistic effects, from improving the ovarian microenvironment, regulating reproductive endocrinology, delaying follicular atresia, etc. which provides a theoretical basis and practical reference for the integrated treatment of DOR. It is suggested that standardised clinical studies should be carried out to establish an evaluation system for the efficacy of TCM and to promote the development of precise treatment options.

中药治疗卵巢储备功能减退的研究进展:机制和临床观察。
卵巢储备减少(DOR)的特征是卵母细胞数量和质量下降,并伴有抗勒氏激素(AMH)减少、窦性卵泡计数(AFC)减少和促卵泡激素(FSH)增加等生物标志物。针对现代医学治疗的局限性,中医药在DOR的治疗中显示出独特的优势。本文系统梳理近十年文献,从分子机制和临床应用两个维度分析中药干预DOR的科学内涵。研究发现,单组分(芍药苷、淫羊藿苷等)、中药对(菟丝子-黑参、白芍-淫羊藿)、中药复方(六味地黄丸、海妇愈愈愈汤、当归-芍药等)以及多种针刺疗法均可通过多靶点调节机制改善卵巢功能:①调节PI3K/AKT等信号通路,促进卵泡发育;②调节下丘脑-垂体-卵巢轴平衡激素水平;③通过Nrf2/HO-1/NLRP3信号通路增强抗氧化应激;④抑制颗粒细胞凋亡相关因子Bax/Caspase-3的表达。临床资料显示,中医药干预可显著提高患者AMH水平,提高AFC水平,降低FSH水平。本研究证实中药通过多成分协同作用,从改善卵巢微环境、调节生殖内分泌、延缓卵泡闭锁等方面发挥治疗优势,为DOR的综合治疗提供理论依据和实践参考。建议开展规范化临床研究,建立中医疗效评价体系,促进精准治疗方案的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Design, Development and Therapy
Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY
CiteScore
9.00
自引率
0.00%
发文量
382
审稿时长
>12 weeks
期刊介绍: Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信